FDA Approves Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection As An Initiation Dose For Early Alzheimer's Disease
14/07/2026 24:31
BRIEF-Eisai Co Ltd - FDA Approves Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection As An Initiation Dose For Early Alzheimer's Disease July 14 (Reuters) - Eisai Co Ltd 4523.T:
EISAI CO LTD: FDA APPROVES LEQEMBI IQLIK (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION AS AN INITIATION DOSE FOR EARLY ALZHEIMER'S DISEASE
Source text: ID:nTSsm90b0b
Further company coverage: 4523.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China